{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"data_sharing_plan":["IPD Sharing (as of September 2021): No"],"condition":["Rectal Neoplasms","Colo-rectal Cancer"],"disease":["Rectal Neoplasms","Colo-rectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2392000"],"location":["China"],"study_start_month":["9"],"keyword":["Cetuximab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts","description":"This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B). All patients in groups A and B will be treated until progression of disease(PD), death, intolerable toxicity or withdrawal of informed consent, whichever occurs first.","dates":{"creation":"2021-09-15"},"accession":"2392000","cross_references":{"ClinicalTrials___gov":["NCT05074966"]}}